Transcode Therapeutics, Inc. (RNAZ) Financial Statements (2026 and earlier)

Company Profile

Business Address 6 LIBERTY SQUARE
BOSTON, MA 02109
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)
Annual | Quarterly

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments17,813,5215,811,0642,767,5984,968,41820,825,860
Cash and cash equivalent17,813,5215,811,0642,767,5984,968,41820,825,860
Receivables953,098  360,229 
Prepaid expense529,04031,563116,607122,42861,459
Deferred costs     934,427
Deposits current assets    9,4109,410
Other undisclosed current assets2,688,2061,250,7111,571,2391,918,920901,019
Total current assets:21,983,8657,093,3384,455,4447,379,40522,732,175
Noncurrent Assets
Operating lease, right-of-use asset  37,731481,694  
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization370,68151,574120,707208,581206,268
Intangible asset, including goodwill, after accumulated amortization140,044,143    
Goodwill25,744,143    
Intangible asset, excluding goodwill, after accumulated amortization114,300,000    
Deferred costs     
Other undisclosed noncurrent assets  111,856111,856  
Total noncurrent assets:140,414,824201,161714,257208,581206,268
TOTAL ASSETS:162,398,6897,294,4995,169,7017,587,98622,938,443
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:3,494,2202,708,1373,051,2594,347,2902,503,569
Employee-related liabilities✕✕✕✕164,657482,237
Accrued liabilities1,461,1101,413,770964,954758,81691,985
Other undisclosed accounts payable and accrued liabilities2,033,1101,294,3672,086,3053,423,8171,929,347
Deferred revenue 25,40827,057 30,528
Other undisclosed current liabilities  38,291412,280  
Total current liabilities:3,494,2202,771,8363,490,5964,347,2902,534,097
Noncurrent Liabilities
Liabilities, other than long-term debt6,590,068 38,291  
Deferred income tax liabilities226,068    
Operating lease, liability   38,291  
Business combination, contingent consideration, liability6,364,000    
Other undisclosed noncurrent liabilities434,3996,541,397   
Total noncurrent liabilities:7,024,4676,541,39738,291  
Total liabilities:10,518,6879,313,2333,528,8874,347,2902,534,097
Equity
Equity, attributable to parent10,335,466(2,018,734)1,640,8143,240,69620,404,346
Common stock92103631,2981,291
Additional paid in capital108,198,36661,183,07948,057,09531,109,64730,708,336
Accumulated deficit(97,862,992)(63,201,916)(46,416,344)(27,870,249)(10,305,281)
Other undisclosed equity, attributable to parent     
Other undisclosed equity141,544,536    
Total equity:151,880,002(2,018,734)1,640,8143,240,69620,404,346
TOTAL LIABILITIES AND EQUITY:162,398,6897,294,4995,169,7017,587,98622,938,443

Income Statement (P&L) (USD)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating expenses(27,980,071)(15,660,697)(19,418,516)(18,665,814)(6,151,135)
Operating loss:(27,980,071)(15,660,697)(19,418,516)(18,665,814)(6,151,135)
Nonoperating income (expense)(6,454,937)(1,094,274)872,4211,100,846(692,264)
Interest and debt expense(6,616)(26,813)(55,899) (95,070)
Loss from continuing operations before equity method investments, income taxes:(34,441,624)(16,781,784)(18,601,994)(17,564,968)(6,938,469)
Other undisclosed income from continuing operations before income taxes6,616    
Loss from continuing operations before income taxes:(34,435,008)(16,781,784)(18,601,994)(17,564,968)(6,938,469)
Income tax expense(226,069)   (53,051)
Other undisclosed loss from continuing operations     
Loss from continuing operations:(34,661,077)(16,781,784)(18,601,994)(17,564,968)(6,991,520)
Loss before gain (loss) on sale of properties:✕✕✕✕✕(6,991,520)
Other undisclosed net income (loss)126,81355,899 148,121
Net loss:(34,661,076)(16,754,971)(18,546,095)(17,564,968)(6,843,399)
Other undisclosed net income attributable to parent     
Net loss attributable to parent:(34,661,076)(16,754,971)(18,546,095)(17,564,968)(6,843,399)
Preferred stock dividends and other adjustments(1,610,211)    
Other undisclosed net loss available to common stockholders, basic (30,601)   
Net loss available to common stockholders, diluted:(36,271,287)(16,785,572)(18,546,095)(17,564,968)(6,843,399)

Comprehensive Income (USD)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Net loss:(34,661,076)(16,754,971)(18,546,095)(17,564,968)(6,843,399)
Comprehensive loss, net of tax, attributable to parent:(34,661,076)(16,754,971)(18,546,095)(17,564,968)(6,843,399)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: